Chinese Hypertriglyceridemia-associated Pancreatitis Study Group (CHPSG): It is NECESSARY to connect the dots between pathophysiology and patient management

Objective: Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) is an increasingly recognized cause of acute pancreatitis, particularly in China. This study aims to establish a multi-center prospective cohort to investigate the prevalence, clinical features, recurrence risk, and complications of HTG-AP, and to provide insights into its pathophysiology and management. Methods: Chinese Hypertriglyceridemia-associated Pancreatitis Study Group (CHPSG) launched a prospective, multicenter observational study across 12 tertiary hospitals in China. Adult patients with acute pancreatitis and serum triglyceride levels >500 mg/dL are enrolled. Standardized case report forms and biological sample protocols are applied to ensure consistency. Clinical and demographic data and biospecimen are collected at baseline and structured follow-up visits for integrated clinical and translational analyses. Results: The CHPSG consortium enables the enrollment of a geographically diverse patient population and the collection of detailed clinical, genetic, and biomarker data. By utilizing the advantages of multi-center studies, such as external validity and larger sample sizes, CHPSG aims to investigate the prevalence, clinical characteristics, natural history, and risk factors of HTG-AP in China. The consortium will also explore the differences between HTG-AP and other etiologies of pancreatitis, with an emphasis on systemic and local complications, recurrence, and long-term quality of life. Through its phased approach, CHPSG seeks to develop targeted strategies for the prevention and treatment of HTG-AP, ultimately improving patient outcomes. Conclusions: This ongoing prospective study provides a unique platform to bridge clinical observations with mechanistic research. Findings are expected to support precision diagnosis, early identification of complications, and the development of targeted therapeutic interventions for HTG-AP.